Pfizer invites applications for its real world data competitive grant in ulcerative colitis programme – Italian experiences opportunity. This supports observational research projects on Tofacitinib in ulcerative colitis clinical management, with an exclusive focus on real world data and real world evidence. Projects should be in relation to one or more of the following topics:
•durable efficacy compared with biologics or immunomodulation across multiple endpoints in all lines of therapy;
•rapid improvement of most relevant patient reported outcomes;
•incidence and prevalence of adverse events in ulcerative colitis patients on tofacitinib compared with corticosteroids, tumour necrosis factor inhibitor, immunomodulator, cardiovascular events, malignancies, serious infections, herpes zoster, and ulcerative colitis-related surgery;
•efficacy and outcomes in young population.
Preference is given to multi-centre protocols.
The PI must be affiliated with an Italy-based institution, and must have a medical or postdoctoral degree, such as a PhD, MD or equivalent.
The budget is €200,000. Up to four grants, worth up to €100,000 each for a maximum of two years, are available.
Deadline: 14th January 2022.